Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15033930 | 0.91 | MAPT (0.42) | GRM5ALDH1A1MAPTMAPK1RAB9A | |
| SCHEMBL15033995 | 0.86 | GRM5 (0.54) | GRM5 | |
| SCHEMBL15033987 | 0.86 | GRM5 (0.42) | GRM5MAPTMAPK1TSHRLMNA | |
| SCHEMBL15033994 | 0.85 | GRM5 (0.46) | GRM5 | |
| SCHEMBL15033971 | 0.84 | GRM5 (0.43) | GRM5ALDH1A1MAPTTSHRRAB9A | |
| SCHEMBL15033970 | 0.82 | GRM5 (0.49) | GRM5ALDH1A1MAPTMAPK1RAB9A | |
| SCHEMBL15034556 | 0.78 | SMN1; SMN2 (0.51) | GRM5ALDH1A1MAPTMAPK1TSHR | |
| SCHEMBL15034006 | 0.77 | ALDH1A3 (0.50) | ALDH1A1MAPTMAPK1RAB9AALDH1A3 | |
| SCHEMBL15034557 | 0.77 | POLB (0.46) | GRM5ALDH1A1MAPTMAPK1TSHR | |
| SCHEMBL15034555 | 0.77 | GRM5 (0.54) | GRM5ALDH1A1MAPTMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791117-B1 | 4-ARYL IMIDAZOLE DERIVATIVES AS MGLU5 POSITIVE ALLESTERIC MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-8716277-B2 | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-8716277-B2 | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-20130158011-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158011-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| WO-2013087807-A1 | 4-ARYL IMIDAZOLE DERIVATIVES AS MGLU5 POSITIVE ALLESTERIC MODIULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158011-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | GRM5 1/4885ALDH1A1 3660/4885MAPT 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.